Method for dermal flap survival growth in reduced circulation with l-norvaline. RU patent 2513619.
 Method for experimental grafting of solid free skin flap / 2513249Solid free skin flap 1.5 cm is formed in a rat. A fascia covering a wound surface is excised, and a subjacent muscle is exposed on an existing bed. The flap is fixed to a skin border along the opposite borders. Free skin borders are sutured together. After 8-9 days, the skin borders fused above the flap are separated and brought apart. |
| Method for controlled mexidol-induced platelet aggregation decrease in experiment / 2512788 Invention refers to medicine, particularly to experimental pharmacology, and concerns methods for controlled platelet aggregation decrease in vitro. That is ensured by administering mexidol to plasma containing 200-220 thousand/mcl of platelets immediately after plasma sampling. Mexidol is used in the concentration of 0.1 to 0.8 mg/ml of an incubation mixture. The incubation is conducted for 10-15 minutes at room temperature. |
| Method for simulating immune-dependent allogenic pregnancy loss in laboratory mice / 2511107 Method involves an intraperitoneal administration of N-acetyl-β-1-O-heptylmuramyl-L-alanyl-D-isoglutamine 20 mcg in 0.9% NaCl 0.1 ml per female laboratory mouse. The preparation is administered on the 5th day of pregnancy in a period of blastocyst implantation and on the 7th day in the beginning of a placentation period. |
| Method for dermal flap survival growth in reduced circulation with resveratrol / 2511061 Dermal flap is simulated in laboratory animals on the second day of experiment. Resveratrol is administered ingragastrically in a daily dose of 2.0 mg/kg from the first experimental days every 46 hours. |
 Forecasting method of potential toxic effect at joint use of several medical preparations / 2510533Invention refers to a field of use of plant objects for control of toxic effect of several medical preparations. The method involves complex evaluation of morphophysiological violations observed in phytotests. Each preparation is tested separately, as well as their liquid mixtures of different concentrations are tested. Morphophysiological violations are found out on garden cress seeds (Lepidium sativum). With that, indices of morphophysiological violations are represented with reduction of germination capacity, reduction of total average length of germs and change of average dry weight of germs. After statistical processing of results a potential toxic effect of a mixture of medical preparations is forecasted. |
 Method for simulating trophic wound in experiment / 2510083Skin is excised to subcutaneous tissue in the form of a circle of the diameter of 20 mm, and a purse suture applied on the periphery of the wound. Fasciocutaneous interrupted sutures are formed. Subcutaneous tissue is excised on the surface of the wound bottom by perpendicular cuts to form cells 5×5 mm. |
 Respiratory phantom impactor / 2509375Respiratory phantom impactor comprises cascade elements placed in a sample bowl built in a body with a pipe fitting attached to an upper part of the body by a threaded connection. Each cascade element, without the last one, consists of a nozzle plate 4, 8, 12, 16, 20, 24, with nozzle holes, a collector plate 6, 10, 14, 18, 22, 26 with a viscous substance coating its surface, and a spacer ring 7, 9, 15, 17, 19, 25, 27; a filter 28 is used as the last cascade element. The seven cascade elements are provided for the gravity sedimentation of aerosols in the respiratory organs. The collector plates 6, 10, 14, 18, 22, 26 are provided for the gravity sedimentation of an aerosol size fraction sedimentary in various parts of the respiratory tract. |
| Method for assessing genetic morphofunctional disorders in white rat offspring with chemical genetic burden / 2509374 White rat offspring behaviour after a toxic exposure is studied with an open-field test. The number of sniffing, locomotion, in-place acts are recorded. A prognostic index is calculated by formula: P=1/(1+e-y), wherein P is the prognostic index that is a probability of genetic variations; e is a mathematical constant equal to 2.72; y is a regression equation: y=7.04-0.65X1+1.45X2-0.64X3, wherein numerical values are constants and regression coefficients; X1 is the number of sniffing acts; X2 is the number of locomotion acts; X3 is the number of in-place acts. If P is more than 0 and less than 0.5, a probability of the genetic variation is stated as minimal, while P more than 0.5 and less than 1 shows a probability of the genetic variations stated as high. |
| Method for simulating fulminant sepsis caused by mixed infection with underlying burning injury / 2507601 Fulminant sepsis is simulated by inducing a mixed infection with underlying a burning injury. For this purpose, a thermal injury of the area of 12-23% of the body surface in anaesthetised rabbits is applied by immersing the back and sides into water at temperature 90° for 10 seconds. That is followed by the subcutaneous introduction of the non-culturable culture Staphylococcus aureus 1.0 ml in the concentration of 105 microbial cells in 1 ml. Then 60 minutes later, the non-culturable culture Pseudomonas aeruginosa is subcutaneously introduced in the amount of 1.0 ml in the concentration of 105 microbial cells in 1 ml. |
 Method and device for simulating infected oral mucosa wound in experiment / 2507600Infected oral mucosa wound is simulated on an internal surface of an animal's lower lip along the midline. That is ensured by applying original retractor clamps according to cl. 2 on the lower lip skin and mucosa. Branches of a Bilroth's hemostatic forceps are used to fix an oral mucosa area 2 mm2 to be turned about a longitudinal axis at an angle of 360°. The mucosa is detached towards the operator. The prepared wound is covered with a cultured bacterial suspension in the amount of 2 ml. The method is implemented with using a device that is the original retractor clamps comprising two plates placed on the lower lip skin and mucosa, coupled with a spring hinge and merging into retractor clamps levers. The plate placed onto the lower lip mucosa has a sharp edged hole of the diameter of 5 mm. The plate placed onto the lower lip skin has a knop having the diameter of 3.5 mm and the height of 2 mm. The inventions may be also used in experimental medicine to study the efficacy of new pharmaceutical preparations on the oral mucosal wound process in experimental animals. |
| Method for regional lymphotropic therapy of paraproctitis / 2513201 Suppurative focus is exposed, drained and sanitated. That is followed by the postoperative subcutaneous administration of drug preparations on the border of middle and lower thirds of leg according to the following regimen: First Lydase dissolved in 0.25% novocaine 2 ml is administered first. After 5-10 minutes, third-generation Cephalosporin 1000 mg dissolved in 0.25% novocaine 5 ml for 5 days is administered. That is followed by administering 4 injections of derinate 5 ml every two days. |
| Method for improving physical condition in young females / 2512838 Invention refers to medicine, namely to sports medicine and physiology, and may be used for improving the physical condition in young females. That is ensured by the 14-day oral sublingual administration of 45° alcoholic solution of royal jelly 3 times a day in a dose of 10 drops, before meals in 17-18-year old female students taking physical exercises. |
 Crystalline forms of 3-carboxypropyl-aminotetralin compound / 2512390Invention provides crystalline solid form of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid or crystalline hydrochloride of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid. Invention relates to pharmaceutical composition, possessing antagonistic activity with respect to mu-opioid receptor, which contains therapeutically effective quality of crystalline solid form. |
| Method for pharmacological correction of skeletal muscle ischemia with l-norvaline / 2507596 Skeletal muscle ischemia in rats is corrected by simulating leg muscle ischemia on the second experimental day. The ischemia is corrected by the intragastric administration of L-norvaline in a daily dose of 10.0 mg/kg from the first experimental day every 46 hours for 7 experimental days. |
| Agent having adaptogenic activity / 2506090 Invention refers to pharmaceutical industry, namely an agent possessing adaptogenic activity. An agent possessing adaptogenic activity, containing ground spiny eleuterococcus roots, snowdone rose roots, Ural licorice roots, bilberry shoots, creeping thyme herb in the certain environment. |
 Compounds for application in visualisation, diagnostics and/or treatment of central nervous system diseases or tumours / 2505528Invention relates to compound of formula Ia , where W represents -C(U1)(U2)-C=CH, U1 and U2, which are independently selected from hydrogen; A is selected from group, containing non-substituted phenyl, non-substituted heteroaryl, the same as furanyl, G1, G2 and G3 in formula Ia are independently and separately, in each case, selected from group, containing hydrogen, (C1-C4)alkyl, preferably methyl, L and (C1-C6)alkyl-L, on condition that it is one of G1-G3 in formula Ia that is selected from L and (C1-C6)alkyl-L, and L represents methylsulfonyloxy group, or L represents F, preferably 18F, n=0, m=0, and to its pharmaceutically acceptable salt. Invention also relates to methods of claimed compound obtaining, compositions, which contain such compounds, for treatment and/or diagnostics and/or visualisation of central nervous system diseases or tumours. |
| Agent for drug-induced correction of nitroxydergic disorders / 2505297 What is presented is using 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide as an active drug base for the purpose of correcting the nitroxydergic malfunctions. |
| Method of treating arterial hypertension with metabolic syndrome / 2504390 Invention refers to medicine, namely to cardiology, and may be used for treating and preventing arterial hypertension with metabolic syndrome. That is ensured by adding the food ration with the functional foodstuff 'Samarskiy Zdorovyak' No 61 in a min daily dose of 33.3 g per one intake - with breakfast or lunch or dinner with underlying drug-induced therapy. |
| Method for pore formation in hepatocyte membranes by bacillus cereus hemolysin ii processing / 2504389 Invention refers to biotechnology and represents a method involving Bacillus cereus hemolysin (HlyII) hemolysin processing of primary membrane hepatocyte and determining the membrane permeability after HlyII processing. Substance of the presented invention consists in the fact that the action of the HlyII preparation on the cell membranes provides the more effective transport of various low-molecular compounds through the cell membranes. The object in view is to form nanometric pores in the hepatocyte membranes ensured by the action of the low concentration of the purified HlyII preparations on the primary hepatocytes. An increase of the hepatocyte membrane permeability after the HlyII preparation processing is determined by microspectral analysis of low-molecular fluorescent dyes. As observed, the increased permeability of the above dyes into the hepatocyte permeability characterises higher permeability of the processed hepatocyte membranes. |
 Agent for extreme performance stimulation, method for preparing and using it / 2503459Group of inventions refers to medicine and concerns an agent for extreme performance stimulation in the form of a mixture of peptides of molecular weight 2000-5000 Da and peptides of molecular weight 500-900 Da prepared of the infant cattle and/or swine brain in ratio of the ingredients 2/1-3/1, in the concentration of the mixture of peptides in the agent of 5.0-10.0 mg/ml of the aqueous solution or 5.0-10.0 mg/g in the witepsol suppository; a method for preparing the above agent for extreme performance stimulation; using the above agent for parenteral administration or for rectal administration. |
 Anticonvulsant and method for preparing it / 2508098Invention refers to medicine, particularly to pharmacology and pharmaceutics, and concerns an anticonvulsant representing the amino acid glycine immobilised on detonation nanodiamond particles 2-10 nm in size, and to a method for preparing it. |
FIELD: medicine.
SUBSTANCE: dermal flap is simulated in laboratory animals on the second day of experiment. L-norvalin is administered intragastrically in a daily dose of 10.0 mg/kg from the first experimental days every 46 hours.
EFFECT: higher dermal flap survival growth in reduced circulation due to the activation of the pre-conditioning process using the pharmacological preparation.
1 tbl
The invention relates to medicine, in particular to the experimental pharmacology and may be used for the correction of ischemia.
Closest to the claimed solution is the way to increase survival rates of skin flap on the leg remote ischemic preconditioning, described Pokrovsky M.V. and co-EN 2429547 C1.
However, this solution does not assesses the influence of L-Norvaline on the survival of the skin flap in the conditions of the reduced circulation.
The advantage of this method is that activation of preconditioning is pharmacological drug. So, no episode ischemia, which could have a damaging effect on the fabric.
The technical result of the invention is development of a method of increasing the survival of the skin flap in the conditions of the reduced circulation, including the use of L-Norvaline.
The technical result is achieved by the fact that the modeling of the skin flap in the conditions of the reduced circulation on the second day of the experiment, laboratory animal administered intragastrically L-Norvaline in a daily dose of 10.0 mg/kg with the first day of every 46 hours of the experiment.
THE METHOD IS AS FOLLOWS
Experiments are carried out on the white Wistar rats weighing 220-250, Modeling of the skin flap is performed under General anesthesia (chloral hydrate 300 mg/kg body weight intraperitoneally) on the second day of the experiment. Stepping back 1 cm from the xiphoid process on the white line of the abdomen, preliminary having planned on a cliche size, cut out the skin flap: 1 cm - base, 4 cm long, (keeping the supply vessel) is sealed in a plastic bag, the edges of the skin is sutured continuous suture. Survival of the skin flap is estimated on the sixth day of the experiment, by measuring the square of the survivors tissue flap in the group of animals with the modeling of the skin flap and in a group with modeling of the skin flap and the introduction of L-Norvaline.
L-Norvaline introduced intragastric in a daily dose of 10.0 mg/kg with the first day of every 46 hours of the experiment.
When aggregated data is calculated mean value, standard deviation. The differences are significant at p<0.05.
A SPECIFIC EXAMPLE.
The experiments were performed on white rats male Wistar mass 220-250, Experimental animals were divided into the following groups:
1) control (n=10);
2) with L-Norvaline (n=10).
Animals of both groups was modeled skin flap on the second day of the experiment. Under anesthesia (chloral hydrate 300 mg/kg body weight intraperitoneally), starting at 1 cm from the xiphoid process on the white line of the abdomen, preliminary having planned on a cliche size, was arranged skin flap: 1 cm - base, 4 cm long, (keeping the supply vessel) insulated in a polyethylene package, edge skin is sutured continuous seam. The animals of the second group was administered intragastrically L-Norvaline in a daily dose of 10.0 mg/kg with the first day of every 46 hours of the experiment.
Estimates of survival of the skin flap was performed on the sixth day of the experiment, by measuring the area of healthy tissue.
The results of the assessment of survival of the skin flap is presented in table 1.
Table 1Survival rates of skin flap in the conditions of the reduced blood flow to the 6th day of the experiment (5 days after modeling) (M±)
Group (n=10)
The area of healthy tissue flap in
cm 2 %Modeling of the skin flap (control)
1,6 of 0.02
40Modeling of the skin flap + L-Norvaline
2,7±0,19*
73Note. * - p < 0,05 when compared with the control group; L-Norvaline intragastric, in a daily dose of 10.0 mg/kg with the first day of every 46 hours experiment
Introduction experimental animals, L-Norvaline contributed to significant (p<0.05) increase the area of survivors tissue flap.
Thus, the obtained results allow to conclude extended survival of the skin flap in the conditions of the reduced circulation, modeled on the second day of the experiment, when intragastric introduction experimental animal L-Norvaline in a daily dose of 10.0 mg/kg with the first day of every 4-6 hours.
The way to increase survival rates of skin flap in the conditions of the reduced circulation, including the modeling of the skin flap in experimental animal, characterized in that the simulation is performed on the second day of the experiment, L-Norvaline administered intragastrically in a daily dose of 10.0 mg/kg with the first day of every 46 PM the experiment.